06.03.2013 • News

Ashland to Expand Pharmaceutical Center of Excellence in Delaware

Ashland today announced plans to expand its pharmaceutical research and development Center of Excellence at the Ashland Research Center in Wilmington. Ashland will be expanding its existing capabilities to include formulation development and Good Manufacturing Processes (GMP) contract manufacturing services for solid dispersions and oral solid dosages.

To support early-stage clinical trials, the expansion will include spray drying and extrusion processes previously located in Columbia, Md. Approximately 20 positions will be relocated from Columbia to Wilmington in connection with the expansion.

The company expects the new facility to be operational by summer 2014. Ashland currently has pharmaceutical technology centers in Buenos Aires, Argentina; Sao Paulo, Brazil; Shanghai, China; Düsseldorf, Germany; Hyderabad, India; Istanbul, Turkey; and Mexico City, Mexico, in addition to Wilmington.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.